Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents

An Open-label, Single-dose, Randomized, Two-way Crossover Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents at Immediate-release Doses of 200 mg and 400 mg.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03633448

Enrollment

Registered

2018-08-16

Start date

2011-06-18

Completion date

2011-07-01

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

Evaluate the pharmacokinetics (PK), Safety and tolerability of guaifenesin (Mucinex®) in an immediate-release formulation when a single dose is administered in adolescents and in adults when compared to Children.

Interventions

DRUGChildren's Mucinex® Grape Flavor

1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. Males and females ≥ 12 and \< 18 years of age or ≥ 18 and \< 55 years of age. All females who were of childbearing potential had to be using one of the following acceptable birth control methods for the time periods specified: 1. Intrauterine device (IUD) in place for at least 3 months prior to Day 1 of Period 1 through 30 days beyond study completion (Day 1 of Period 2). 2. Barrier method (condom or diaphragm) with spermicide for at least 7 days prior to screening through 30 days beyond study completion (Day 1 of Period 2) 3. Stable hormonal contraceptive (oral, depo injection, transdermal patch, or vaginal ring) for at least 3 months prior to Day 1 of Period 1 through 30 days beyond completion of study (Day 1 of Period 2). Note: Abstinence (sexually inactive) was not an acceptable form of contraception; however, abstinent female subjects could have been admitted to the study if they agreed, and had signed a statement to the effect, that upon becoming sexually active, would use a condom with spermicide from that time through 30 days beyond completion of the study (Day 1 of Period 2). Females ≥ 18 years of age of non-childbearing potential must have been surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to Day 1 of Period 1 or hysterectomy and/or bilateral oophorectomy at least 3 months prior to Day 1 of Period 1) or post-menopausal ≥ 2 years prior to Day 1 of Period 1. A follicle stimulating hormone (FSH) level \> 40 miU/mL must have been obtained and in the record for any post-menopausal female experiencing their last menses \< 2 years prior to Day 1 of Period 1. 2. Negative urine pregnancy test at Screening and each Check-in for all female subjects. 3. Good general health as determined by the PI's review of medical history, physical examination, vital sign measurements (after 2 minutes resting in the seated position), and clinical laboratory measures. 4. For subjects ≥ 18 and \< 55 years of age, body mass index (BMI) of 19 to 29 kg/m2, inclusive. (BMI = weight (kg)/\[height (m)\]2). 5. Subjects ≥ 12 and \< 18 years of age had to be \> 5th percentile and less than the 95th percentile for weight and BMI of ≥ 18 to ≤ 28 kg/m2 based on age and gender. 6. Non-tobacco users, who had not used nicotine or nicotine-containing products for at least 1 year prior to Day 1 of Period 1. 7. Negative finding on tests for hepatitis B surface antigen (HBsAG), hepatitis C virus (HCV) antibodies, human immunodeficiency virus (HIV). 8. Negative urine screen for drugs of abuse and alcohol at Screening and each Check-in. 9. Likely to be compliant and complete the study, and if \< 18 years of age had parent(s) or legally authorized representative(s) likely to be compliant with study requirements, according to the PI. 10. Able to read, understand, and sign the informed consent, after the nature of the study had been explained, and had read, signed, and dated an IRB-approved informed consent/assent form for subjects to participate in the study. Additionally, for subjects \< 18 years of age, a parent(s) or legally authorized representative(s), had to read, sign, and date an IRB-approved informed consent/assent form for subjects \< 18 years of age to participate in the study. 11. Subjects \< 18 years of age must have met the following at-risk requirements: 1. Frequency - a history of frequent upper respiratory infections (URIs) defined as \> 4 infections per year for adolescents aged ≥ 12 to \< 18 yrs, AND; 2. Exposure - Another family member in the home who was ill with URI/common cold or a child in the family who was attending preschool or school with ≥ 6 children in the group, AND; 3. Crowding - Greater than (\>) 4 persons living in the home or \> 3 persons sleeping in one bedroom.

Exclusion criteria

1. Clinically significant abnormalities detected by medical history, physical examination, vital sign measurements, ECG findings, or clinical laboratory findings (as determined by the PI), including a hemoglobin value \< 12 gm/dL at Screening. 2. Females who were pregnant or nursing. 3. History of hypersensitivity reaction to guaifenesin or to EMLA® cream (eutectic mixture of local anesthetic) or its components (lidocaine + prilocaine as local anesthetic). 4. Receipt of an investigational drug within 30 days prior to Day 1 of Period 1. 5. Abnormal diet (for whatever reason) during the 30 days prior to Day 1 of Period 1. 6. Donation of blood or significant loss of blood within 56 days prior to Day 1 of Period 1. 7. Donation of plasma within 14 days prior to Day 1 of Period 1. 8. Known or suspected use of illicit drugs (i.e., opiates, barbiturates, marijuana, et. al.). 9. The use of any medication on a chronic basis, with the exception of hormonal contraceptives for women of child-bearing potential. An appropriate drug free period for prescription or OTC drugs should have been provided to wash out any especially long half-life drugs. 10. Alcoholism or medicinal product or drug abuse within the past two years or excessive alcohol consumption (more than 10 units per week) (one unit was defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of spirits (i.e., hard liquor such as gin, whiskey, or vodka, et. al.). The subject was not to experience tolerance, withdrawal, compulsive use, or substance related problems such as medical complications, disruption in social and family relationships, vocational or financial difficulties, or legal problems. 11. Consumption of grapefruit, pummelo, Seville orange or grapefruit juice within 14 days prior to dosing with study medication. Subjects had to be willing to abstain from consuming any of these products during the study. 12. Related to persons involved directly or indirectly with the conduct of this study (i.e., PI, Sub-Investigators, Study Coordinators, other study personnel, employees of Reckitt Benckiser, and the families of each). Subject

Design outcomes

Primary

Measure	Time frame	Description
Apparent First-order Terminal Elimination Rate Constant (Kel)	0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours	Apparent first-order terminal elimination rate constant calculated from a semilog plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares (LS) regression analysis using the maximum number of points (e.g., three or more non-zero plasma concentrations) in the terminal log-linear phase.
Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin	0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours	Area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration, as calculated by the linear trapezoidal method.
Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin	0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours	Area under the plasma concentration versus time curve from time 0 to infinity, calculated as AUC 0-t + C last/kel, where C last is the last measurable concentration and kel is the apparent first-order terminal elimination rate constant.
Percent of AUC 0-inf Extrapolated (AUC%Extrapolated)	0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours	Percent of AUC 0-inf extrapolated, calculated as (1 - AUC 0-t / AUC 0-inf) x 100.
Maximum Observed Plasma Concentration (Cmax) of Guaifenesin	0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours	Pharmacokinetic Parameter (Cmax) Maximum observed plasma concentration.
Time to Maximum Observed Concentration (Tmax) of Guaifenesin	0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours	Pharmacokinetic Parameter (Tmax) Time of the maximum observed plasma concentration.
Apparent First-order Terminal Elimination Half-life (t½)	0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours	Apparent first-order terminal elimination half-life, calculated as ln(2)/kel.

Secondary

Measure	Time frame	Description
Number of Adverse Events (AEs) of Participants	Upto Day 1	Intensity determination: Mild=AE does not limit usual activities;subject may experience slight discomfort; Moderate= AE results in some limitation of usual activities; subject may experience significant discomfort; Severe=AE results in an inability to carry out usual activities; subject may experience intolerable discomfort or pain; Unlikely=Slight but remote chance that the AE was caused by study drug but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug; Probable=Most likely that the AE was caused by study drug.

Participant flow

Recruitment details

This was a single-centre study.

Pre-assignment details

Total 24 subjects were enrolled in the study and all 24 completed the study.

Participants by arm

Arm	Count
Adolescent Treatment A: Single 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate Release by oral syringe under overnight fast. Treatment B: Single 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate Release by oral syringe under overnight fast. There was a 7 days washout period between each administration.	12
Adult Treatment A: Single 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate Release by oral syringe under overnight fast. Treatment B: Single 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate Release by oral syringe under overnight fast. There was a 7 days washout period between each administration.	12
Total	24

Baseline characteristics

Characteristic	Adolescent	Adult	Total
Age, Continuous	14.3 Years STANDARD_DEVIATION 1.71	32.2 Years STANDARD_DEVIATION 12.42	23.2 Years STANDARD_DEVIATION 12.6
Body Mass Index	20.78 kg/m^2 STANDARD_DEVIATION 1.482	23.98 kg/m^2 STANDARD_DEVIATION 3.168	22.38 kg/m^2 STANDARD_DEVIATION 2.917
Ethnicity Hispanic or Latino	1 Participants	0 Participants	1 Participants
Ethnicity Non-Hispanic and Non-Latino	11 Participants	12 Participants	23 Participants
Height	163.9 cm STANDARD_DEVIATION 7.69	166.83 cm STANDARD_DEVIATION 10.954	165.35 cm STANDARD_DEVIATION 9.379
Race Asian	1 Participants	2 Participants	3 Participants
Race Black or African American	10 Participants	8 Participants	18 Participants
Race White	1 Participants	2 Participants	3 Participants
Sex: Female, Male Female	7 Participants	8 Participants	15 Participants
Sex: Female, Male Male	5 Participants	4 Participants	9 Participants
Weight	56.03 kg STANDARD_DEVIATION 7.198	66.88 kg STANDARD_DEVIATION 11.611	61.45 kg STANDARD_DEVIATION 10.955

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 12	0 / 12	0 / 12	1 / 12
other Total, other adverse events	0 / 12	0 / 12	0 / 12	1 / 12
serious Total, serious adverse events	0 / 12	0 / 12	0 / 12	0 / 12